Oligonucleotide Therapeutics - From Concept to Implementation Agenda
World Trade Center Boston
200 Seaport Boulevard
Boston, MA 02210
Oligonucleotide Therapeutics - From Concept to Implementation Agenda
Drug Discovery

Schedule of Presentations:

Monday, August 3, 2009
07:30:00 Registration and Coffee
08:30:00 Conference Chair Opening Remarks James H Thompson
08:35:00 Featured Presentations
08:40:00 Oligonucleotide Therapeutics - Where We've Been and Where We're Going Cy Stein,
09:10:00 Tod Woolf, Ph.D. Thirty Years of Targeting RNA: A Retrospective Tod Woolf
09:15:00 Delivery Challenges and Novel Delivery Systems
09:40:00 Development of SNALP Formulated siRNA-based Drugs Ian MacLachlan
10:05:00 Efficient GeRP-Mediated Oral Delivery of siRNA to Macrophages to Modulate Inflammation in Mice Gary R. Ostroff
10:30:00 Networking Refreshment Break
11:00:00 Peptide-Mediated Muscle Delivery of Morpholino Oligomers for Treatment of Duchenne Muscular Dystrophy Hong Moulton
11:25:00 RNAi Therapeutics: Delivery and Mechanism Michael V. Templin
11:50:00 Nanoparticle-Enhanced and Multi-Targeted siRNA Therapeutics for Critical Human Diseases Patrick Y. Lu
12:15:00 Meet & Greet Networking Luncheon
12:20:00 Specificity & Toxicity Considerations in Developing Oligonucleotide Therapeutics
13:55:00 Chairperson's Remarks Patrick Y. Lu
14:00:00 Strategies for Developing RNAi Therapeutics(tentative title) Satish Chandran
14:25:00 Strategies for Designing Antisense Oligonucleotides with Improved Therapeutic Margins Richard S. Geary
14:50:00 Are Target and Off-Target Regulation by RNAi Therapeutics Conserved Across Species? Aimee Jackson
15:15:00 Toxicology Considerations in the Development of a Therapeutic based on Transkingdom RNA Interference (tkRNAi) Jens Harborth
15:40:00 Networking Refreshment Break
16:15:00 Attendee/Speaker Chat Sessions
16:20:00 Regulatory - What's the Status, Relationship & Treatment of RNAi Compound?
16:25:00 Maximizing Therapeutic Oligo Manufacturing Efficiency via Customer and CMO Partnerships Paul Metz
16:45:00 Survey of the IP Landscape Brian H. Johnston
16:50:00 Delivery Innovations and Breakthroughs
16:50:00 Current & Future Developments of miRNA Aimee Jackson
16:55:00 RNAi for Target Validation
17:00:00 Challenges and Limitations of In Vivo Models for Oligo Therapeutics
17:05:00 Special Aspects of Oligonucleotide Radiochemistry Dan McPherson
17:10:00 Development of Robust Supply Chains to Support GMP Manufacturing of Oligonucleotide Therapeutics Emma Wright
17:15:00 Chat Sessions Round-Up
18:00:00 Attendee Networking Dinner in Boston
Tuesday, August 4, 2009
08:30:00 Conference Chair Opening Remarks William S. Marshall,
08:35:00 The Different Stages of Drug Development (Discovery to PreClinical to Clinical) for siRNA, miRNA, Antisense and Aptamers
08:40:00 Preclinical- and Clincial Development of Atu027, a Liposomal siRNA, for Oncology Klaus Giese
09:05:00 Design and Development of Synthetic siRNAs for Clinical Applications James H Thompson
09:30:00 Development of Novel RNAi Therapeutic Compounds and In Vivo Delivery Approaches Dmitry Samarsky
09:55:00 Evaluating the Structure and Energy Contributions of Base Mismatches Francois Major
10:20:00 Networking Refreshment Break in Exhibit & Poster Hall
11:00:00 Novel, Highly Potent Designs for shRNAs Targeting Hepatitis C Virus Brian H. Johnston
11:25:00 A Novel Dual Inhibitory Function Anti-HIV Envelop Aptamer-siRNA Chimera John Rossi
11:30:00 Industry Leadership Forum
11:50:00 RNA Therapeutics - Are We Leveraging on the Promise? James H Thompson, Paul Burke, Klaus Giese, Tod Woolf
12:30:00 Networking Luncheon in Exhibit & Poster Hall
12:35:00 The Different Stages of Drug Development (Discovery to PreClinical to Clinical) for siRNA, miRNA, Antisense and Aptamers (continued)
13:55:00 Chairperson's Remarks Dmitry Samarsky
14:00:00 Spiegelmers® advance towards clinical trials Sven Klussmann,
14:25:00 microRNA Manipulation as a Therapeutic Strategy for Cardiovascular Disease William S. Marshall,
14:50:00 Therapeutic Applications of Tumor Suppressor miRNAs Matt Winkler
15:15:00 LNA Antimirs - Pioneering miRNA Therapeutics Henrik Ørum
15:40:00 Networking Refreshment Break in Exhibit & Poster Hall
16:25:00 Antisense Oligonucleotide GED-0301 Against Smad7 for the Oral Treatment of Crohn's Disease Francesca Viti,
16:50:00 Recent Advances in Aptamer Therarpeutics: Discovery and Initial Characterization of an Anti-hepatocyte Growth Factor Aptamer Kristin M. Thompson
17:15:00 Close of Oligonucleotide Therapeutics Conference and Proceed to Plenary Keynote
17:20:00 Keynote Introduction Osamu Sato
17:20:00 Plenary Keynote
17:25:00 Takashi Shoda Global Pharma Innovator: Daiichi Sankyo's Challenge to Build a Competitive Pharmaceutical Company in the Global Market Takashi Shoda
18:00:00 Cocktail Reception in Exhibit & Poster Hall
3D Tissue Models
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.